# WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

> **NCT06967805** · PHASE2 · RECRUITING · sponsor: **Mediar Therapeutics** · enrollment: 164 (estimated)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **BIOLOGICAL:** MTX-463
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06967805
- **Lead sponsor:** Mediar Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-05
- **Primary completion:** 2027-08
- **Final completion:** 2027-08
- **Target enrollment:** 164 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06967805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06967805, "WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06967805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*